Burnham & Co LLC Invests $1.95 Million in Johnson & Johnson $JNJ

Key Points

• Burnham & Co. LLC initiated a $1.95 million position in Johnson & Johnson during the second quarter, buying 7,667 shares. J&J now represents 1.6% of the firm’s portfolio, while institutional investors collectively own 69.55% of the stock.
• Johnson & Johnson exceeded quarterly expectations, reporting adjusted EPS of $2.90 versus the $2.84 consensus and revenue of $25.31 billion, up 6.6% year over year. The company reaffirmed fiscal 2026 EPS guidance of $11.60–$11.75.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $272.83. J&J also declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% annualized yield.

Burnham & Co LLC acquired a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,667 shares of the company's stock, valued at approximately $1,947,000. Johnson & Johnson comprises 1.6% of Burnham & Co LLC's portfolio, making the stock its 19th biggest holding.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Auto Owners Insurance Co raised its holdings in shares of Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after buying an additional 69,108,368 shares during the period. Norges Bank purchased a new position in Johnson & Johnson during the 4th quarter valued at about $6,924,523,000. Capital World Investors acquired a new position in Johnson & Johnson in the 4th quarter valued at about $2,005,942,000. Diamant Asset Management Inc. grew its position in Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock valued at $109,338,000 after acquiring an additional 4,454,778 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Johnson & Johnson by 41.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company's stock worth $2,571,124,000 after purchasing an additional 3,655,754 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: UBS initiated coverage of Johnson & Johnson (JNJ) with a Buy rating and a $320 target, reflecting expectations that the company’s pharmaceutical pipeline can support stronger growth. J&J Jumps as UBS Lifts Its Target to $320
• Positive Sentiment: Healthcare stocks broadly moved higher, with the NYSE Healthcare Index gaining 0.7%, creating a favorable backdrop for JNJ and other defensive healthcare names. Sector Update: Healthcare Stocks Advance Wednesday
• Positive Sentiment: Management will participate in a Deutsche Bank Healthcare Summit fireside chat on September 17. The event could provide additional commentary on the drug pipeline, growth outlook and capital allocation, although no new financial guidance was announced. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Johnson & Johnson Price Performance

JNJ stock opened at $275.63 on Thursday. The business has a 50 day moving average price of $260.90 and a 200 day moving average price of $244.61. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a market cap of $664.25 billion, a price-to-earnings ratio of 31.94, a PEG ratio of 2.59 and a beta of 0.24. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's payout ratio is presently 62.11%.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. HSBC set a $290.00 price target on shares of Johnson & Johnson and gave the company a "buy" rating in a research report on Monday, July 6th. Argus set a $300.00 price objective on Johnson & Johnson in a research note on Wednesday, July 29th. The Goldman Sachs Group reiterated a "buy" rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $272.83.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 63,972 shares of company stock valued at $16,245,605 in the last 90 days. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source